Kenneth J. O’Byrne

Author

Kenneth J. O’Byrne

Queensland University of Technology ORCID

Also Known As

Artyom Sedrakyan, Carlos Barrios, Cathcart Mary-Clare, G. Sozzi, Honn, K V, Honn, Kenneth V., K Byrne, K J O'Byrne, K J O’Byrne, K O'Byrne

1.2K

Publications

48.4K

Citations

H-Index

159

Concepts

All Affiliations

Queensland University of Technology Princess Alexandra Hospital St. James's Hospital Translational Research Institute Trinity College Dublin

About

Kenneth J. O’Byrne is an author at Queensland University of Technology specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	57	158	14.1K
2	Health Sciences	20	33	3.6K
3	Natural Sciences	8	8	206
4	Engineering	6	6	216
5	Public Health	1	1	21

Kenneth J. O’Byrne

289

Publications

37.6K

Citations

H-Index

Page 1

	Year	Citations
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, New England Journal of Medicine	2013	3.4K
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Journal of Clinical Oncology	2013	3.2K
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, New England Journal of Medicine	2018	3.1K
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabé, New England Journal of Medicine	2019	2.8K
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Michel Marty, Francesco Cognetti, D Maraninchi, IRIS UNIMORE (University of Modena and Reggio Emilia)	2005	1.6K
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, The Lancet Oncology Lux-lung 3Lux-lung 6MedicinePathologyBronchial Neoplasm	2015	1.6K
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, The Lancet MedicineMetronomic TherapyPhase Iii TrialBronchial NeoplasmCancer Treatment	2009	1.4K
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne, The Lancet Oncology OncologyPhase 2BPathologyBronchial NeoplasmAfatinib Versus Gefitinib	2016	1.1K
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study Tom Treasure, Loı̈c Lang-Lazdunski, David Waller, The Lancet Oncology	2011	706
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers Neal Ready, Matthew D. Hellmann, Mark M. Awad, Journal of Clinical Oncology	2019	584

Page 1